Browse > Article
http://dx.doi.org/10.22246/jikm.2022.43.2.184

A Case Report of Nonalcoholic Fatty Liver Disease with Obesity and Dyslipidemia  

Kim, Eujin (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University)
Hwang, Cho-Hyun (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University)
Lee, Juyoung (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University)
Jang, Eungyeong (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University)
Kim, Youngchul (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University)
Lee, Jang-Hoon (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University)
Publication Information
The Journal of Internal Korean Medicine / v.43, no.2, 2022 , pp. 184-190 More about this Journal
Abstract
Objectives: This study aims to report the clinical efficacy of Korean medical treatment of a patient with nonalcoholic fatty liver disease accompanied by obesity and dyslipidemia. Methods: A 52-year-old man with nonalcoholic fatty liver disease, obesity, and dyslipidemia was treated with Saenggangunbi-tang extract from November 3, 2021 to January 8, 2022. During the treatment period, the patient also undertook exercise and maintained a hypocaloric diet to reduce body weight. Changes were observed in the patient's symptoms, laboratory findings, such as liver enzymes and lipid profiles, and bioelectrical impedance analyzer results. Results: After taking Saenggangunbi-tang extract for approximately two months, with concomitant adjustments to exercise and diet, the serum levels of liver enzymes and triglyceride were decreased and the patient's body weight, body mass index, hepatic steatosis index, and visceral fat area were also reduced. In addition, symptoms including fatigue and dyspepsia improved. Conclusion: This study suggests that Saenggangunbi-tang extract with exercise and a regulated diet could be a helpful treatment strategy for managing nonalcoholic fatty liver disease with metabolic disorders.
Keywords
nonalcoholic fatty liver disease; Saenggangunbi-tang; case report;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Yang HJ, Park JK, Kwon SY, Woo HJ, Lee JH, Kim YC. A clinical study of 5 cases of patients who have nonalcoholic fatty liver disease(NAFLD) treated by Saenggangeonbi-tang. J Int Korean Med 2011;spr(1):141-51.
2 Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 2010;51(2):679-89.   DOI
3 Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010;42(7):503-8.   DOI
4 Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002;17 Suppl: S186-90.   DOI
5 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97.   DOI
6 Sorrentino G, Crispino P, Coppola D, De Stefano G. Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study. Drugs R D 2015;15(1):21-5.   DOI
7 Woo HJ, Lee JH, Kim YC, Kim GS, Son CK, Jo JH, et al. Oriental Internal Medicine on Hepatobiliary System, Hematology and Toxicology 6th. Seoul: Nado; 2016, p. 307-15.
8 Kim HY, Joo SH, Bae JH, Jang EG, Kim YC, Lee JH. A case report of nonalcoholic steatohepatitis with metabolic Syndrome. J Int Korean Med 2017;38(2):125-30.
9 Milic S, Lulic D, Stimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol 2014;20(28):9330-7.   DOI
10 Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med 2020;17(4):e1003100.   DOI
11 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatology 2018;67(1):328-57.   DOI
12 Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA 2020;323(12):1175-83.   DOI
13 Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016;65(8):1109-23.   DOI
14 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73-84.   DOI
15 Reginato E, Pippi R, Aiello C, Sbroma Tomaro E, Ranucci C, Buratta L, et al. Effect of short term intensive lifestyle intervention on hepatic steatosis indexes in adults with obesity and/or type 2 diabetes. J Clin Med 2019;8(6):851.   DOI
16 Kim BW. Clinical analysis and the effect of Saenggangunbitang on 3,136 cases of the chronicle hepatitis patients. The Journal of Korean Oriental Medicine 1993;14(1):216-23.
17 Choi ES, Kim HY, Cho YH, Jang EG, Woo HJ, Kim YC, et al. A case report of adolescent nonalcoholic fatty liver disease (NAFLD) with severe obesity. J Int Korean Med 2015;spr(1):89-95.
18 Yoon SK. Diagnosis and treatment of fatty liver. Korean J Med 2009;76(6):677-9.
19 Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 2017;377(21):2063-72.   DOI
20 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, et al. KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27(3):363-401.   DOI